Monkeypox – Next p(L)andemic on Its Way? Christine Anderson

The following text contains some premium conspiracy theories on the subject of “monkeypox”. At least that’s what those who believe in what the TV tells them would claim. But because almost all of the old conspiracy theories have come true in the meantime, we are now getting a new supply:

As you probably know, the WHO has already issued the highest global health alert for monkeypox (Mpox) last week, although the spread is only limited to some regions of Africa.

You probably also know that a simulation game on the topic of “monkeypox” took place at the Munich Security Conference in 2021. One of the participants was Jeremy Farrar, the then director of the billion-dollar health foundation “Wellcome Trust” (funded by the Bill & Melinda Gates Foundation, among others). As luck would have it, Farrar has been Chief Scientist at the WHO since last year.

At the end of 2023, BioNTech enters into a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI was founded in Davos in 2016 (WEF sends its regards) and is an alliance of the WHO, the EU Commission, individual governments, pharmaceutical companies, (private) donors and foundations. The “Wellcome Trust”, the Gates Foundation and the UN stand out in the 2024 investor overview.

In May 2024, BioNTech and CEPI announced that they are expanding their portfolio for mRNA vaccines – including vaccines against Mpox. At the same time, the monkeypox vaccine “Imvanex” from “Bavarian Nordic” is already being produced in Denmark and is the only one to be approved in both the EU and the USA.

So much for the crystal-clear facts. If you want to find out more, here is a good place to start.

In the meantime, during my own research, I came across further, rather disturbing information:

Did you know that the Austrian Red Cross (Tyrol section) for example, is now looking for new employees for vaccination centers? The tasks include managing patient flows, preparing barcodes and vaccination certificates as well as carrying out mobile vaccinations. Applicants are expected to be “assertive”, among other things. From the end of September, the new employees will receive a gross salary of around €2,450 per month at their place of work in Vienna.

BioNTech previously announced in the German business newspaper Handelsblatt that they expect 90 percent of their total sales to be generated by the end of 2024. 

Currently, BioNTech is building its first commercial African vaccine factory in Rwanda. The focus here also includes mRNA vaccines against Mpox.

Some old acquaintances traveled to the opening: EU Commission President Ursula von der Leyen and German Foreign Minister Annalena Baerbock gave themselves the dubious honor.

Incidentally, Germany is supporting the development of the vaccine production in Rwanda with almost 36 million euros of German taxpayers’ money.

Dear readers, do you believe in coincidences?

I DO NOT!

Christine Margarete Anderson is a German politician who has been serving as a Member of the European Parliament since 2019.

*

Click the share button below to email/forward this article to your friends and colleagues. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

One Month Before Global Research’s Anniversary 

Featured image is from Christine Anderson


Articles by: Christine Anderson

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]